AU2019318046B2 - Histone demethylase 5 inhibitors and uses thereof - Google Patents

Histone demethylase 5 inhibitors and uses thereof Download PDF

Info

Publication number
AU2019318046B2
AU2019318046B2 AU2019318046A AU2019318046A AU2019318046B2 AU 2019318046 B2 AU2019318046 B2 AU 2019318046B2 AU 2019318046 A AU2019318046 A AU 2019318046A AU 2019318046 A AU2019318046 A AU 2019318046A AU 2019318046 B2 AU2019318046 B2 AU 2019318046B2
Authority
AU
Australia
Prior art keywords
certain embodiments
optionally substituted
compound
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019318046A
Other languages
English (en)
Other versions
AU2019318046A1 (en
Inventor
Paul M. PARK
Chengkui PEI
Jun Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019318046A1 publication Critical patent/AU2019318046A1/en
Application granted granted Critical
Publication of AU2019318046B2 publication Critical patent/AU2019318046B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019318046A 2018-08-06 2019-08-06 Histone demethylase 5 inhibitors and uses thereof Active AU2019318046B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862715122P 2018-08-06 2018-08-06
US62/715,122 2018-08-06
US201862715687P 2018-08-07 2018-08-07
US62/715,687 2018-08-07
US201962803332P 2019-02-08 2019-02-08
US62/803,332 2019-02-08
PCT/US2019/045259 WO2020033377A1 (en) 2018-08-06 2019-08-06 Histone demethylase 5 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2019318046A1 AU2019318046A1 (en) 2021-01-14
AU2019318046B2 true AU2019318046B2 (en) 2025-02-13

Family

ID=69414411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019318046A Active AU2019318046B2 (en) 2018-08-06 2019-08-06 Histone demethylase 5 inhibitors and uses thereof

Country Status (6)

Country Link
US (1) US20230382865A1 (https=)
EP (1) EP3833347A4 (https=)
JP (1) JP2021534084A (https=)
AU (1) AU2019318046B2 (https=)
CA (1) CA3106548A1 (https=)
WO (1) WO2020033377A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11232861B1 (en) 2021-06-18 2022-01-25 Argos Health Inc. Systems and methods for displaying predetermined information for clinical use
WO2024233765A1 (en) * 2023-05-09 2024-11-14 Ohio State Innovation Foundation Therapeutic approach to block terminal exhaustion of t cells and synergize the efficacy of t cell immunotherapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014053491A1 (en) * 2012-10-02 2014-04-10 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014131777A1 (en) * 2013-02-27 2014-09-04 Epitherapeutics Aps Inhibitors of histone demethylases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
BRPI0415179A (pt) * 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
WO2012162291A1 (en) * 2011-05-24 2012-11-29 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
EP3102193B1 (en) * 2014-02-06 2023-01-11 Rutgers, The State University of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
EP3126345A1 (en) * 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
SG11201701182VA (en) * 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014053491A1 (en) * 2012-10-02 2014-04-10 Epitherapeutics Aps Inhibitors of histone demethylases
WO2014131777A1 (en) * 2013-02-27 2014-09-04 Epitherapeutics Aps Inhibitors of histone demethylases

Also Published As

Publication number Publication date
AU2019318046A1 (en) 2021-01-14
CA3106548A1 (en) 2020-02-13
EP3833347A4 (en) 2022-04-27
JP2021534084A (ja) 2021-12-09
EP3833347A1 (en) 2021-06-16
WO2020033377A1 (en) 2020-02-13
US20230382865A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
EP3544970B1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
AU2020301399B2 (en) HCK degraders and uses thereof
US12564591B2 (en) HCK as a therapeutic target in MYD88 mutated diseases
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US10865213B2 (en) Max binders as MYC modulators and uses thereof
EP3814365B1 (en) Dot1l degrader and uses thereof
US20220242872A1 (en) E3 ligase binders and uses thereof
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
AU2020205665C1 (en) DOT1L degraders and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)